Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 10, 2012, Pages 1618-1627

  Vinh Hung, Vincent ^b   Everaert, Hendrik ^a   Lamote, Jan ^a   Voordeckers, Mia ^a   Van Parijs, Hilde ^a   Vanhoeij, Marian ^a   Verfaillie, Guy ^a   Fontaine, Christel ^a   Vees, Hansjoerg ^b   Ratib, Osman ^b   Vlastos, Georges ^b   De Ridder, Mark ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Breast cancer; Lymph nodes; Prognosis; Staging; Surgery; Survival

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST; BREAST CANCER; BREAST SURGERY; CANCER DIAGNOSIS; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS, MALE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84868208873     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2181-1     Document Type: Article

References (37)

1. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11:iii-267.
2. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. Med Sci Monit. 2007;13:RA37-46.
3. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Cancer Netw. 2009;7 Suppl 2:S1-26.
4. Escalona S, Blasco JA, Reza MM, Andradas E, Gomez N. A systematic review of FDG-PET in breast cancer. Med Oncol. 2010;27:114-29.
5. Peare R, Staff RT, Heys SD. The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2010;123:281-90.
6. Avril N, Adler LP. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. Radiol Clin North Am. 2007;45:645-57. vi.
7. Groheux D, Hindie E, Espie M, et al. Interests and perspectives of PET-CT for breast cancer: review of the literature. Bull Cancer. 2007;94:658-68.
8. Lim HS, YoonW, Chung TW, et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics. 2007;27 Suppl 1:S197-213.
9. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27 Suppl 1:S215-29.
10. Pons F, Duch J, Fuster D. Breast cancer therapy: the role of PETCT in decision making. Q J Nucl Med Mol Imaging. 2009;53:210-23.
11. Almubarak M, Osman S, Marano G, Abraham J. Role of positronemission tomography scan in the diagnosis and management of breast cancer. Oncology (Williston Park). 2009;23:255-61.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 1.2011. 2010; Available via: http://www.nccn.org. Accessed 30 Nov 2010.
13. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F] -D-glucose. Cancer. 1998;82:2227-34.
14. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-9.
15. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D- glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273-8.
16. Mercier-Vogel L, Couson F, Kohlik M, Bodmer A. Impact of breast MRI and PET-CT in breast cancer staging. Rev Med Suisse. 2010;6:1076-8. 1080.
17. Bral S, Vinh-Hung V, Everaert H, De CP, Storme G. The use of molecular imaging to evaluate radiation fields in the adjuvant setting of breast cancer: a feasibility study. Strahlenther Onkol. 2008;184:100-4.
18. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16:219-42.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
20. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model, vol. 87. New York: Springer-Verlag; 2000.
21. Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006; 24:2910-6.
22. Venables WN, Ripley BD. Modern applied statistics with S, vol. 172. 4th ed. New York: Springer-Verlag; 2002.
23. Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours, vol. 181. 7th ed. Oxford: Wiley-Blackwell; 2009.
24. Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062-8.
25. Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166-70.
26. Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250-8.
27. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15:588-93.
28. Groves AM, Shastry M, Rodriguez-Justo M, et al. (18)F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46-52.
29. Nakajo M, Kajiya Y, Kaneko T, et al. FDG PET/CT and diffusionweighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging. 2010;37:2011-20.
30. Tozaki M, Hoshi K. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors. AJR Am J Roentgenol. 2010;194:1384-90.
31. Osborne JR, Port E, Gonen M, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med. 2010;51:543-50.
32. Jung SY, Kim SK, Nam BH, et al. Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17:247-53.
33. Vinh-Hung V, Truong PT, Janni W, et al. The effect of adjuvant radiotherapy on mortality differs according to primary tumor location in women with node-positive breast cancer. Strahlenther Onkol. 2009;185:161-8.
34. Morris PG, Ulaner GA, Eaton A, et al. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer 2012. doi:10.1002/cncr.27579.
35. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
36. Avril A, Le BG, Lorimier G, et al. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up. Eur J Surg Oncol. 2011;37:563-70.
37. Vinh-Hung V, Vees H. FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer. ClinicalTrials gov 2011; Available via: http://clinicaltrials.gov/ct2/show/NCT01432002. Accessed 8 Sep 2011.